RxDoctor Payments Data

Arianna Sholes, MD

Obstetrics & Gynecology · Tucson, AZNPI 1679519730

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $16,223 of the $20,852 with a category attached, or 77.8%. Astellas Pharma US Inc accounts for 90.2% of it on its own, with 13 other manufacturers making up the rest. Among obstetrics & gynecology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,852in general payments, 2019–2025

Across 67 payments — averaging $311.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$19K
  • Bayer$426
  • Galderma Laboratories, L.p.$415
  • Merz North America, Inc.$394
  • Revance Therapeutics, Inc.$305
  • AbbVie$176
  • plus $325 from 8 others

What the payments were for

  • Speaking & faculty fees$16,22378%
  • Travel & lodging$1,8399%
  • Food & beverage$2,68213%
  • Education$1081%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,852 in reported general payments places this provider in the 95th percentile of 757 obstetrics & gynecology providers in Arizona.

See all obstetrics & gynecology providers in Arizona

Medicare billing

Part B allowed, 2024
$10,489
Medicare patients
39
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProgesteroneProgesterone, Micronized31$709
Liothyronine Sodium12$534
Armour ThyroidThyroid,pork12$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieArmour Thyroid$176$38512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 757 obstetrics & gynecology providers in Arizona.

Other obstetrics & gynecology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →